Welcome to our dedicated page for CNS Pharmaceuticals news (Ticker: CNSP), a resource for investors and traders seeking the latest updates and insights on CNS Pharmaceuticals stock.
CNS Pharmaceuticals reports news about its clinical-stage biotechnology business and its strategy to build a neurology and oncology pipeline. Company updates commonly address anti-cancer drug candidates for primary and metastatic cancers of the brain and central nervous system, including TPI 287 and Berubicin, as well as clinical-data presentations and regulatory-development planning.
Recurring developments also include executive leadership changes, pipeline prioritization, business-development strategy, financial results, capital-allocation commentary, shareholder voting matters, governance updates and capital-structure disclosures tied to its Nasdaq-listed common stock.
CNS Pharmaceuticals announced a registered direct offering and concurrent private placement, raising approximately $1.98 million before expenses. The company will sell 1,425,000 shares of common stock at $1.39 each, along with warrants to purchase an equal number of shares at $1.26 per share, exercisable immediately and expiring in 5 years. The closing is expected around July 5, 2024, pending customary conditions. Net proceeds will support working capital and general corporate purposes. The offering is conducted under an effective shelf registration statement and a private placement exemption.
CNS Pharmaceuticals announced a registered direct offering and concurrent private placement, selling 568,000 shares of common stock and issuing warrants for an additional 568,000 shares. The combined purchase price per share and warrant is $2.45, with warrants exercisable at $2.32. The gross proceeds are expected to be around $1.39 million before expenses.
The offering will close around June 27, 2024, pending customary conditions. Net proceeds will go towards working capital and general corporate purposes. The shares will be issued under an effective shelf registration statement filed with the SEC, while the warrants will be issued under an exemption from registration requirements.
CNS Pharmaceuticals (NASDAQ:CNSP) announced a securities purchase agreement with institutional investors, involving a registered direct offering of 366,000 shares of common stock and warrants to purchase up to another 366,000 shares. The combined purchase price is $3.75 per share, and the warrants have an exercise price of $3.62, expiring in 5 years. The offering is expected to close around June 17, 2024, bringing in gross proceeds of $1.37 million. The net proceeds will be used for working capital and general corporate purposes. The offering is based on a registration statement declared effective by the SEC on May 17, 2024.
CNS Pharmaceuticals (NASDAQ: CNSP) announces a 1-for-50 reverse stock split effective June 4, 2024, aiming to boost per-share price and comply with Nasdaq's minimum share price listing requirement.
From June 5, 2024, CNSP shares will trade on a split-adjusted basis under the new CUSIP number 18978H300.
All outstanding common stock, warrants, equity-based awards, and other equity rights will be proportionally adjusted. No fractional shares will be issued; instead, stockholders entitled to fractional shares will receive the nearest whole number.
The par value of the stock remains $0.001, and the authorized shares remain at 300 million.
CNS Pharmaceuticals, a biopharmaceutical company focused on brain and central nervous system cancer treatments, announced that its CEO, John Climaco, will participate in a fireside chat at Alliance Global Partner's 2024 Healthcare Company Showcase.
The event is scheduled for May 21, 2024, at 1:40 PM ET and will be webcast live on the company's website.
CNS Pharmaceuticals (NASDAQ: CNSP) announced its financial results for Q1 2024, reporting a net loss reduction to $3.5 million from $4.9 million in Q1 2023. This decrease is attributed to lower research and general administrative expenses. The company's R&D expenses dropped to $2.4 million from $3.6 million, primarily due to the timing of its pivotal Berubicin trial costs.
General administrative expenses also decreased to $1.1 million. The company has completed enrollment for its Berubicin trial for glioblastoma multiforme (GBM) and expects topline data in H1 2025. Berubicin has received both Fast Track and Orphan Drug designations from the FDA. As of March 31, 2024, CNS had $0.8 million in cash.
Summary not available.
Summary not available.
Summary not available.
Summary not available.